Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis

BACKGROUND: Although EGFR-TKI is the preferred treatment for NSCLC patients with sensitive mutations, subsequent drug resistance is almost inevitable. The specific mechanisms of EGFR-TKI drug resistance can be identified through repeat biopsy. METHODS: To better understand the clinical characteristi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zan-Feng, Ren, Sheng-Xiang, Li, Wei, Gao, Guang-Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801841/
https://www.ncbi.nlm.nih.gov/pubmed/29409466
http://dx.doi.org/10.1186/s12885-018-4075-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801841/
https://www.ncbi.nlm.nih.gov/pubmed/29409466
http://dx.doi.org/10.1186/s12885-018-4075-5

Ejemplares similares